nirogacestat 100 MG (equivalent to nirogacestat HBr 133.05 MG) Oral Tablet
- RxCUI
- 2680360
- RxNorm name
- nirogacestat 100 MG (equivalent to nirogacestat HBr 133.05 MG) Oral Tablet
- Display name
- nirogacestat 100 MG (equivalent to nirogacestat HBr 133.05 MG) Oral Tablet
- Full name
- nirogacestat 100 MG (equivalent to nirogacestat HBr 133.05 MG) Oral Tablet
- Term type
- SY
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:27
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| OGSIVEO | NIROGACESTAT | SpringWorks Therapeutics, Inc. | f172e6ff-3190-41b0-b95a-58a7ef9e9e1e | 2026-03-26 | Warnings, Adverse reactions | 2680360 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| f172e6ff-3190-41b0-b95a-58a7ef9e9e1e | nirogacestat 100 MG (equivalent to nirogacestat HBr 133.05 MG) Oral Tablet | SY | 14 | These highlights do not include all the information needed to use OGSIVEO safely and effectively. See full prescribing information for OGSIVEO. OGSIVEO ® (nirogacestat) tablets, for oral use Initial U.S. Approval: 2023 | 20260326 |
| f172e6ff-3190-41b0-b95a-58a7ef9e9e1e | nirogacestat 100 MG Oral Tablet | PSN | 14 | These highlights do not include all the information needed to use OGSIVEO safely and effectively. See full prescribing information for OGSIVEO. OGSIVEO ® (nirogacestat) tablets, for oral use Initial U.S. Approval: 2023 | 20260326 |
| f172e6ff-3190-41b0-b95a-58a7ef9e9e1e | nirogacestat 100 MG Oral Tablet | SCD | 14 | These highlights do not include all the information needed to use OGSIVEO safely and effectively. See full prescribing information for OGSIVEO. OGSIVEO ® (nirogacestat) tablets, for oral use Initial U.S. Approval: 2023 | 20260326 |